Private preview | selected clients

Travel vaccines: the whole arc, one analysis.

The existing-vaccine module is complete - travel-attributed sales isolated from endemic and routine use, and split to country level across 13 vaccines and 13 markets. The forecast to 2040 is in preparation, framed in three scenarios anchored to IATA long-term air passenger demand, and scopes the emerging development pipeline.

Private preview for selected clients | figures reserved. From VacZine Analytics MarketVIEW: Travel Vaccines (VAMV090). Analysis current July 2026.

13
travel vaccines
de-layered from franchises
13
origin markets
US/Canada | EU5 | Nordics | JP/KR/AU
169
country-level cells
each anchored & weighted
2040
forecast horizon
three IATA-anchored scenarios
Market trajectory

From pandemic collapse to recovery - and modelled to 2040

We track the traveller vaccine market across its full arc: the pandemic trough, the recovery powered by returning travel and new launches (chikungunya, dengue), and a forward view to 2040. Travel-attributed sales are separated cleanly from endemic and routine use - the traveller market on its own terms.

Travel vaccines: the whole arc, one analysis Pandemic collapse to recovery - forecast to 2040 in three scenarios 2019 2020 2025 2030 2035 2040 HIGHBusiness-as-usual air travel;robust GDP (IATA ~3.3% CAGR) BASEOrderly energy transition;(IATA mid ~3.1% CAGR) LOWDisorderly transition, highercosts (IATA low ~2.9% CAGR) Recovery + new launches chik | dengue Forecast to 2040 [ scenarios in preparation ] Pandemic trough Relative market value (axis values withheld) New products scoped in the forecast pipeline Arboviral Zika virus Enteric & other Campylobacter, Shigella, Lyme disease, Norovirus, Malaria, new ETEC, other Illustrative development pipeline - candidates that could reshape the market to 2040 Forecast scenarios anchored to IATA Long-Term Air Passenger Demand Projections to 2050 (iata.org) Travel-attributed sales isolated from endemic & routine use 13 products de-layered from company franchises - the traveller market, cleanly separated to the country level. Existing-vaccine module complete | Forecast to 2040 in preparation vaczine-analytics.com
Relative market trajectory - axis values withheld. Forecast scenarios anchored to IATA Long-Term Air Passenger Demand Projections to 2050.
The forecast module also scopes the emerging development pipeline in two groups - arboviral (Zika virus) and enteric & other (Campylobacter, Shigella, Lyme disease, Norovirus, Malaria, new ETEC, and others) - the candidates most likely to reshape the traveller market to 2040.
ReservedAbsolute travel-attributed values and the full 2040 scenario set are available to clients under the MarketVIEW report.
Depth

Country-specific - to the cell

Every one of the 13 vaccines is split across 13 markets: 169 country-level estimates, each anchored to disclosed company actuals where they exist, then apportioned by pathogen-specific outbound travel and graded by confidence. Not a top-down guess - a bottom-up build.

13 vaccines. 13 markets. Every cell.Country-specific estimates - anchored, weighted, confidence-tiered US CA UK DE FR IT ES SE NO DK JP KR AU Cholera ETEC/Dukoral Hep A/B Hep A Hep B Meningitis JE (Ixiaro) Rabies TBE Typhoid Yellow Fever Chikungunya Dengue Anchored to actuals Pathogen-specific weighting Confidence-tiered (1/2/3) Country-level figures quantified for all 169 cells - values reserved for clients. Existing-vaccine module complete | Forecast to 2040 in preparationvaczine-analytics.com
Coverage across 13 vaccines and 13 markets. Cell values quantified in the report; withheld here.
Methodology

Demand modelled, not assumed

Each vaccine is weighted by destination-specific outbound travel - rabies-endemic regions, Japanese encephalitis in rural Asia, the meningitis belt plus Hajj and Umrah pilgrimage, yellow-fever entry mandates, the Aedes tropics for dengue and chikungunya, and TBE forest zones. Pathogen risk, entry mandates and pilgrimage, market by market.

Demand modelled, not assumedThe real drivers behind each traveller vaccine - by pathogen and market Origin markets US & Canada UK EU5 (DE/FR/IT/ES) Nordics Japan Australia South Korea Demand drivers & destinations Rabies - Asia/Africa/LatAm Japanese encephalitis - rural Asia Meningitis belt + Hajj/Umrah Yellow Fever entry mandates Aedes tropics - dengue/chik TBE forest zones - C/N Europe Weighted by destination-specific outbound travel Not generic trip counts - pathogen risk, entry mandates and pilgrimage, market by market. Existing-vaccine module complete | Forecast to 2040 in preparationvaczine-analytics.com
Origin markets mapped to the real drivers of each traveller vaccine.
Transparency

Confidence, made explicit

Every figure is graded so its reliability is visible. The large majority of lines are anchored to disclosed company actuals or audited regional splits; only two are fully modelled and flagged as directional. You always know where the evidence is strongest.

Confidence tiers How each country estimate is graded - disclosed fact vs. analyst model 1 Actual - disclosed Taken directly from a company disclosure. 2 Actual-anchored estimate Anchored to a disclosed split or share; the remainder is modelled. 3 Fully modelled estimate No disclosed country actual; total and split are analyst estimates. Source: VacZine Analytics MarketVIEW - Travel Vaccines 2026 vaczine-analytics.com
Confidence tiers applied line by line across the analysis.
Regulatory footprint

Where each product can actually sell

Revenue is only allocated where a product is licensed. The traffic-light map captures traveller-market availability across the modelling countries - the newer franchises (chikungunya, dengue) carry the sharpest restrictions.

Travel vaccine licensing - traveller-market availability Analyst assessment across the modelling countries, July 2026 - verify against local regulators before external use US CA UK DE FR IT ES SE NO DK JP KR AU Cholera (Vaxchora) ETEC / Dukoral Hepatitis A/B Hepatitis A Hepatitis B Meningitis ACWY Japanese Enceph. (Ixiaro) Rabies Tick-Borne Enceph. Typhoid Yellow Fever Chikungunya Dengue (Qdenga) Licensed / available Restricted / limited / verify Not licensed on traveller market US United States | CA Canada | UK | DE Germany | FR France | IT Italy | ES Spain | SE Sweden | NO Norway | DK Denmark | JP Japan | KR South Korea | AU Australia Source: VacZine Analytics MarketVIEW - Travel Vaccines 2026; company/regulator disclosures vaczine-analytics.com
Traveller-market availability, analyst assessment (July 2026). Illustrative - verified per product in the report.
VacZine Analytics | MarketVIEW: Travel Vaccines (VAMV090)

Request the country-level figures and 2040 scenarios

This preview shows the structure and depth of the analysis; the absolute values, full country splits and forecast scenarios are reserved for clients. Contact us for a private walkthrough or to license the report.

View the report page Request a briefing